Navigation Links
Are we cherry picking participants for studies of antidepressants?
Date:4/28/2009

PITTSBURGH, April 28 Findings from clinical studies used to gain Food and Drug Administration approval of common antidepressants are not applicable to most patients with depression, according to a report led by the University of Pittsburgh Graduate School of Public Health. Published in the May issue of the American Journal of Psychiatry, the study suggests only a small percentage of people with depression qualify for these studies, and those who do not qualify are often treated with the same medications but may suffer poorer clinical outcomes.

A part of the National Institute of Mental Health-funded Sequenced Treatment Alternatives to Relieve Depression (STAR*D) project the largest study of the treatment of depression conducted in the United States researchers compared symptoms and outcomes in depressed patients who met phase III study inclusion criteria to those who did not. Phase III studies for antidepressants determine the effectiveness of the drug in comparison to a placebo. The inclusion criteria for these studies are not standardized nor subject to federal guidelines, resulting in some variation from study to study in the profile of eligible patients. Typically excluded are patients with milder forms of depression, who might be more likely to respond to a placebo drug, and those who may have chronic depression or psychiatric and medical co-morbidities additional illnesses or conditions.

After assessing 2,855 patients treated with citalopram, a commonly prescribed selective serotonin reuptake inhibitor for mood disorders, study authors concluded that fewer than one in four, or 22.2 percent, of the patients met the usual criteria for inclusion in phase III antidepressant trials.

"Only a small percentage of depressed patients in our study would have qualified for inclusion in phase III efficacy trials of depression drugs," said study lead author, Stephen Wisniewski, Ph.D., professor of epidemiology and co-director of the Epidemiology Data Center, University of Pittsburgh Graduate School of Public Health. "This raises major concerns about whether results from traditional phase III studies can be generalized to most people with depression, who also often suffer from anxiety, substance abuse and other medical and psychiatric problems."

When Dr. Wisniewski and colleagues further assessed how well patients did on treatment, they found that those who met the eligibility criteria for phase III trials had better outcomes, including higher remission rates, less severe side effects and serious adverse events. The depression remission rate in the patients who met the criteria was 34.4 percent, compared to only 24.7 percent in the ineligible group. Additionally, the drug response rate also was higher in the eligible group 51.6 percent compared to 39.1 percent of the ineligible group.

"Results from research studies suggest more optimistic outcomes than may exist for real-world patients receiving treatment for depression," said Dr. Wisniewski. Although phase III eligibility criteria could be changed to include a broader population of patients, Dr. Wisniewski cautions that this could come at the cost of more serious side effects in patients who have co-morbidities and are generally sicker. These patients may not be able to safely tolerate the drugs being tested. Instead, he suggests medical care providers who treat patients with depression use their professional judgment by noting that most phase III findings are based on patients who may be very different than those under their care.


'/>"/>

Contact: Clare Collins
CollCX@upmc.edu
412-647-3555
University of Pittsburgh Schools of the Health Sciences
Source:Eurekalert

Related medicine news :

1. Cherrybrook Kitchen Announces New Partnership With Arthur
2. Credit Union Cherry Blossom Ten Mile Run Cherry Blossom Ten-Miler Raises $400,000 For Children's National Medical Center
3. 7UP Gives Consumers a New Reason to Fall in Love - New Cherry 7UP Antioxidant
4. Cherry-Enriched Diet Cut Heart Risks in Rats
5. Foundation Radiology Group and Cherry Tree Medical Associates Sign Multi-Year Contract for Diagnostic Services
6. Reported Health Benefits of Tart Cherry Boosts Juice Distribution in Southern U.S.
7. Hoffa, Cherry to Speak at Community Rally Supporting Genesys Nurses
8. Sleep Medicine Associates Opens New Doors at Swedish - Cherry Hill Campus
9. Picking the Right Toys Isnt Childs Play
10. Paragon Technologies SI Systems Brand Awarded A $1.0 Million System Expansion Contract for an Automated Light-Picking System
11. Innovation and Strategic Alliances Come to the Rescue of Participants in Mature Brazilian Market for Food Emulsifiers, Finds Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... July 24, 2017 , ... Cheerag D. Upadhyaya , ... Marion Bloch Neuroscience Institute (SLMBNI), part of Saint Luke’s Health System . ... , Cheerag D. Upadhyaya, MD. M.Sc., FAANS joins Stanley P. Fisher, M.D., ...
(Date:7/24/2017)... ... July 24, 2017 , ... BayMark Health Services ... Health Services Administration’s (SAMHSA) State Targeted Response to the Opioid Crisis program. ... will facilitate the development of a hub and spoke model for opioid treatment ...
(Date:7/24/2017)... ... July 24, 2017 , ... Peruvian Ayahuasca retreat, ... be awarded annually to and divided between two full-time university students enrolled in ... Amazonian plant medicine. To apply for the scholarship, students are asked to submit ...
(Date:7/24/2017)... ... July 24, 2017 , ... Axiad IDS , a leading provider ... partnered with WALLIX to expand its solution to help government contractors more ... a number of ways to address the authentication requirements within NIST SP800-171, but ...
(Date:7/24/2017)... ... 24, 2017 , ... A CDC study shows that, although people are taking more steps to ... 29), had at least one case of sunburn within the past year. It’s common and ... ignore the issue. However, only recently have people become conscientious of the risks that accompany ...
Breaking Medicine News(10 mins):
(Date:7/20/2017)... -- Prime Therapeutics LLC (Prime) released this statement from its Chief ... for Clinical and Economic Review,s (ICER) public meeting ... of abuse-deterrent formulations (ADF) of opioids. Prime was the sole ... "The ICER data ... use of abuse-deterrent formulations (ADF) in opioids in terms of ...
(Date:7/14/2017)... It should come as no surprise to anyone that ... of a crippling opioid epidemic. According to the Center ... deaths from opiate-based medications has quadrupled, Says, Dr. David ... 2001 to 2015". During this time, the prescription rate for ... a compelling link between prescription and eventual addiction. The problem ...
(Date:7/12/2017)... , July 12, 2017  Eli Lilly and Company (NYSE: ... with generic companies to resolve pending patent litigation in the ... Virginia regarding the Cialis ® (tadalafil) unit ... April 26, 2020. As part of the agreement, Cialis exclusivity ... 27, 2018. "The unit dose patent for Cialis ...
Breaking Medicine Technology: